The recent acquisitions of Ergomed and Instem underscore an emerging trend: private equity entities seeking out undervalued UK life sciences firms that have been constrained by AIM’s insufficient capital resources.
Amryt Pharma plc (AMYT.L) Update on Regulatory Review Process for Oleogel-S10
DUBLIN, Ireland, and Boston MA, November 23 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
Share Talk Weekly Stock Market News, Sunday 13th September 2020
We hope you had a great week in the markets and are all staying safe, our newsletter is going out later today so without further ado, let us look back
Amryt Pharma PLC (AMYT.L) POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
AMRYT ANNOUNCES POSITIVE TOP LINE RESULTS FROM PIVOTAL PHASE 3 “EASE” TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
Amryt Pharma Plc (AIM:AMYT) New distribution agreement signed
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has signed an exclusive distribution agreement for Lojuxta® (lomitapide) covering Romania and Bulgaria with